Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

Cancer

Volumn 101, Issue 7, 2004, Pages 1569-1574

  Smith, Matthew R ^a   Manola, Judith ^b   Kaufman, Donald S ^a   George, Daniel ^b   Oh, William K ^b   Mueller, Elisabetta ^b   Slovin, Susan ^c   Spiegelman, Bruce ^b   Small, Eric ^d   Kantoff, Philip W ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Peroxisome proliferator activated receptor ; Prostate carcinoma; Prostate specific antigen; Rosiglitazone

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ROSIGLITAZONE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EDEMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE SPECIFIC ANTIGEN DOUBLING TIME; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 4844219655     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20493     Document Type: Article

References (16)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
3. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158:1441-1445.
4. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997;44:213-221.
5. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002;20:4567-4573.
6. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
7. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421-424.
8. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci USA. 2000;97:10990-10995.
9. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344-3352.
10. 12,14-prostaglandin J2. Cell Growth Dif. 2000;11:49-61.
11. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984;40:819-825.
12. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24:308-315.
13. Moyad MA. The placebo effect and randomized trials: analysis of conventional medicine. Urol Clin North Am. 2002;29:125-133, ix-x.
14. Rini BI, Weinberg V, Bok R, Small EJ. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003;21:99-105.
15. Beer TM, Lemmon D, Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer. 2003;97:1217-1224.
16. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res. 2003;9:1-9.